Clinical Trial Update: A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of Recurrence

View source ↗

Summary

This is a non-interventional study evaluating the use of ribociclib (Kisqali) in combination with an aromatase inhibitor as adjuvant therapy for HR+/HER2- early…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Aromatase inhibitor (Aromatase inhibitor)
• KISQALI (ribociclib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Breast Neoplasms | Status: RECRUITING